Möchten Sie immer auf dem neuesten Stand bleiben?

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First...

Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO,...

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 15, 2025 it granted stock options to purchase an aggregate...

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the...

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297...

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...

CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Incorporated, (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of...

LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...

System of Care to Advance Care for the Most Commonly Inherited Heart Disease SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) --  Cytokinetics, Inc. (Nasdaq: CYTK) today announced its...